Cost variation analysis of oral anti-diabetic agents available in Indian market

Sanjay Gedam*, Namita Barmaiya

Department of Pharmacology, NSCB MC, Jabalpur, Madhya Pradesh, India

Received: 20 April 2021
Accepted: 11 May 2021

*Correspondence:
Dr. Sanjay Gedam,
Email: drsanjay1981@gmail.com

ABSTRACT

Background: The objective of this study was to analyze cost variations of oral antidiabetic drugs available in Indian market.

Methods: An observational study was carried out using CIMS (current index of medical specialities), (July 2020 to October 2020) and 1 mg.com, where difference in the maximum and minimum price of a particular drug, manufactured by different pharmaceutical companies, in the same strength, number and dosage form was compared and the percentage variation in price was calculated. Data was analyzed using descriptive statistical analysis.

Results: The minimum and maximum percentage price variation for different classes of drugs respectively is as follows- in single drug therapy, the price variation between a sulfonylurea group of drugs glibenclamide (5 mg) shows maximum price variation of 400%, while glipizide (2.5 mg) shows variation of 81.8%. In biguanides, thiazolidinediones and DPP4 inhibitor groups of drugs, metformin (500 mg), pioglitazone (30 mg) and vildagliptin show maximum price variation of 334.78%, 307 % and 264.6% respectively. In α-glucosidases inhibitor group of drugs voglibose (0.2 mg) shows maximum price variation of 284%. In meglitinides group of drugs, nateglinide (60 mg) shows maximum price variation of 284.6 %. In combination drug therapy, glimepiride and metformin combination (2+500 mg SR) shows the maximum variation up to 352.8%.

Conclusions: The percentage cost variation of different brands of the same drug manufactured in India is very wide and the reason behind marketing a drug should be directed towards maximizing the benefit of therapy and minimizing negative personal and economic consequences.

Keywords: Price variation, Oral anti diabetic drugs, Cost variation, Cost ratio, Diabetes mellitus

INTRODUCTION

Diabetes is a chronic metabolic disorder associated with significant morbidity and mortality affecting almost 6.2% of world population.1

Diabetes mellitus is reaching possibly epidemic proportions in India. India had 69.2 million people living with diabetes (8.7%) as per the 2015 data-an increase of over 10 million from 2011 when estimates suggested that about 50.8 million people in the country were suffering from the disease. By the year 2030, over 100 million people in India are likely to suffer from diabetes.2,3

Type 2 diabetes is a disease marked by high levels of blood glucose due to insufficient insulin synthesis and release. Type 2 diabetes accounts for approximately 90% to 95% of all diagnosed cases of diabetes.4

It is accompanied with abnormal carbohydrate, protein and lipid metabolism. Diabetes if uncontrolled can lead to several acute and chronic complications.5,6
Type 2 diabetes mellitus requires lifelong treatment. In case of absence of appropriate treatment, it can lead to microvascular and macrovascular complications. These can affect the longevity as well as the quality of life.¹

For successful treatment, appropriate drug regime with regular follow up and the proper compliance to the treatment play an important role. For the treatment of a condition which requires lifelong treatment, various factors can affect the compliance. Drug cost can play an important role in long term compliance to the treatment.

In India, where majority of the population is not covered by any insurance, the cost of treatment expenses is mainly out of pocket. Significant fraction of population is dragged below the poverty line every year due to these out of pocket expenses for the treatment. It is a chronic disorder which needs lifelong treatment. Cost association is very large with treatment of diabetes. Type 1 diabetes mellitus is to be treated with insulin whereas in Type 2 diabetes, oral anti diabetic drugs are used. Drug should be selected on the basis of its efficacy, major side effects and also on patients’ clinical characteristics like body mass index (BMI), presence of other disease, financial background/socioeconomic status.

There are over 20,000 drug formulations are available in Indian market with different brand names. Sometimes it is difficult for physician to select appropriate drug because of unavailability of information on comparative drug prices.

Indian pharmaceuticals market is the third largest market in terms of volume and thirteenth largest market in terms of value. Indian pharmaceuticals market is dominated by branded generics which constitutes about 70 to 80 percent of the market.²³ India being the largest provider of generic drugs globally accounts for 20 percent of global exports in terms of volume. The focus of this study was at comparing and analyzing the costs of various brands of the same generic oral anti diabetic drugs, so that authors can study their cost variations. Awareness of the cost variations among oral anti diabetic drugs can be applied to ensure more economical treatment regimen to improve the treatment adherence and the rate of success of therapy.

**Aim**

The aim of the study was to evaluate the cost of oral anti-diabetics of different brand names of one compound and the difference in cost of different brands of the same active drug by calculating percentage variation of cost.

**Objectives**

The objective of this pharmacoeconomic study was designed with the main objectives of- (a) to find different anti-diabetics available either singly or in combination and the number of the brands available for each; (b) to evaluate the cost of oral anti-diabetics of different generic classes and different brand names of one compound; and (c) to evaluate the difference in cost of different brands of the same active drug by calculating percentage variation of cost.

**METHODS**

The study was undertaken in the department of pharmacology at NSCB medical college Jabalpur Madhya Pradesh.

Analysis of data was done using CIMS- current index of medical specialities’ (July-October 2020) and 1 mg.com, they were reviewed for the prices of different oral hypoglycaemic drugs used in the management of diabetes mellitus. (a) The maximum retail price of a particular drug being manufactured by different companies, in the same strength, number and dosage form was compared. (b) The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies was calculated. (c) The percentage variation in price was calculated.

The percentage variation in price was calculated using the following formula,

\[
\text{Percentage cost variation} = \frac{(\text{Price of most expensive brand} - \text{Price of least expensive brand})}{\text{Price of least expensive brand}} \times 100
\]

**RESULTS**

The prices on a total of 20 drugs (12 single and 8 combination preparations), available in 45 different formulations were analyzed.

These 45 formulations are manufactured by different pharmaceutical companies.

In single drug therapy, Table 1 shows the price variation between a sulfonylurea group of drugs. In this group, glibenclamide (5 mg) shows maximum price variation of 400%, while glipizide (2.5 mg) shows variation of 81.8%. Table 2 shows price variation in biguanides, thiazolidinediones and DPP4 Inhibitor groups of drugs. In these groups, metformin (500 mg), pioglitazone (30 mg) and vildagliptin show maximum price variation of 334.78%, 307% and 264.6% respectively.
Table 1: Cost variation among sulfonylureas.

| Drug     | Formulation | Strength in mg | Least expensive price (INR) | Most expensive price (INR) | Cost ratio | Cost variation (%) | No. of brands |
|----------|-------------|----------------|-----------------------------|----------------------------|------------|--------------------|---------------|
| Glibenclamide | Tab         | 2.5            | 4.75                        | 10                         | 2.1        | 110.5              | 6             |
|          | Tab         | 5              | 8                           | 40                         | 5          | 400                | 5             |
| Gliclazide   | Tab         | 40             | 17.5                        | 50                         | 2.8        | 185.7              | 9             |
|          | Tab         | 80             | 30                          | 83                         | 2.7        | 176.67             | 14            |
|          | SR          | 30             | 31                          | 69                         | 2.2        | 122.5              | 05            |
|          | SR          | 60             | 52                          | 125                        | 2.4        | 140.38             | 06            |
| Glimepiride | Tab         | 1              | 15                          | 39.31                      | 2.6        | 162.06             | 43            |
|          | Tab         | 2              | 23                          | 81                         | 3.5        | 152.17             | 44            |
|          | Tab         | 4              | 40                          | 172                        | 4.3        | 330                | 11            |
| Glipizide  | Tab         | 2.5            | 2.75                        | 5                          | 1.8        | 81.8               | 02            |
|          | Tab         | 5              | 4.55                        | 11                         | 2.4        | 141.75             | 06            |
|          | Tab         | 10             | 10.36                       | 22                         | 2.1        | 112.35             | 02            |

Tab- tablet, SR- sustained release

Table 2: Cost variation among biguanides, thiazolidinediones and DPP-4 inhibitors.

| Drug     | Formulation | Strength in mg | Least expensive price (INR) | Most expensive price (INR) | Cost ratio | Cost variation (%) | No. of brands |
|----------|-------------|----------------|-----------------------------|----------------------------|------------|--------------------|---------------|
| Metformin| Tab         | 500            | 6.9                         | 30                         | 4.3        | 334.78             | 31            |
|          | SR          | 500            | 12.59                       | 31.26                      | 2.48       | 149                | 18            |
|          | SR          | 1000           | 24                          | 59.91                      | 2.5        | 149.6              | 11            |
| Pioglitazone | Tab       | 15             | 19                          | 53                         | 2.79       | 178.9              | 12            |
|          | Tab         | 30             | 20.51                       | 83.48                      | 4.07       | 307                | 12            |
| Teneligliptin | Tab     | 20             | 55                          | 139                        | 2.75       | 152.7              | 18            |
| Vildagliptin | Tab       | 50             | 82                          | 299                        | 3.6        | 264.6              | 8             |

Tab- tablet, SR- sustained release

Table 3: Cost variation among α-glucosidases inhibitor.

| Drug     | Formulation | Strength in mg | Least expensive price (INR) | Most expensive price (INR) | Cost ratio | Cost variation (%) | No. of brands |
|----------|-------------|----------------|-----------------------------|----------------------------|------------|--------------------|---------------|
| Voglibose| Tab         | 0.2            | 21                          | 85.69                      | 3.8        | 284                | 26            |
|          | Tab         | 0.3            | 29.5                        | 135                        | 3.7        | 272                | 27            |
| Acarbose | Tab         | 25             | 47.25                       | 79                         | 1.59       | 60                 | 5             |
|          | Tab         | 50             | 90                          | 128                        | 1.56       | 56                 | 6             |

Tab- tablet, SR- sustained release

Table 4: Cost variation among meglitinides.

| Drug     | Formulation | Strength in mg | Least expensive price (INR) | Most expensive price (INR) | Cost ratio | Cost variation (%) | No. of brands |
|----------|-------------|----------------|-----------------------------|----------------------------|------------|--------------------|---------------|
| Nateglinide | Tab        | 60             | 19.5                        | 75                         | 3.8        | 284.6              | 31            |
|          | Tab        | 120            | 29.5                        | 110                        | 3.7        | 272.9              | 29            |
| Repaglinide | Tab        | 0.5            | 22                          | 75                         | 3.4        | 241                | 10            |
|          | Tab        | 1              | 44                          | 145                        | 3.3        | 230                | 10            |
|          | Tab        | 2              | 78                          | 231.65                     | 3          | 197                | 6             |

Tab- tablet

Table 3 shows the price variation between α-glucosidases inhibitor group of drugs. In this group, voglibose (0.2 mg) shows maximum price variation of 284%.

Table 4 shows the price variation between meglitinides group of drugs. In this group, nateglinide (60 mg) shows maximum price variation of 284.6%.
**Combination therapy**

In combination therapy, total 8 combination preparations were analyzed.

**Table 5: Cost variation among fixed dose combinations.**

| Drug                        | Formulation | Strength in mg | Least expensive price (INR) | Most expensive price (INR) | Cost ratio | Cost variation (%) |
|-----------------------------|-------------|----------------|----------------------------|----------------------------|------------|--------------------|
| Glibenclamide+metformin     | Tab         | 5+500          | 16                         | 51                         | 3.2        | 218.75             |
| Gliclazide+metformin        | Tab         | 80+500         | 40                         | 100                        | 2.5        | 150                |
| Glimepiride+metformin       | Tab         | 1+500          | 39                         | 65                         | 1.67       | 66.67              |
|                             | Tab         | 2+500          | 41                         | 78                         | 1.9        | 90.24              |
|                             | Tab         | 2+1000         | 58                         | 159                        | 2.7        | 174.14             |
|                             | SR          | 1+500          | 36                         | 86                         | 2.39       | 138.89             |
|                             | SR          | 2+500          | 36                         | 163                        | 4.5        | 352.8              |
| Glipizide+metformin         | Tab         | 2.5+500        | 5.14                       | 22                         | 4.3        | 328                |
|                             | Tab         | 5+500          | 11.64                      | 50                         | 4.3        | 329.5              |
| Pioglitazone+metformin      | Tab         | 15+500         | 36.4                       | 84                         | 2.3        | 130.8              |
|                             | SR          | 15+500         | 42                         | 113.84                     | 2.7        | 171                |
|                             | SR          | 30+500         | 62.35                      | 86.2                       | 1.38       | 38.25              |
| Pioglitazone+glimepiride    | Tab         | 15+1           | 19.25                      | 53.80                      | 2.8        | 179.5              |
|                             | Tab         | 15+2           | 40                         | 137                        | 3.4        | 242.5              |
| Voglibose+metformin         | Tab         | 0.2+500        | 49                         | 100                        | 2.04       | 104.08             |
|                             | Tab         | 0.3+500        | 58.9                       | 115                        | 1.95       | 95.25              |
| Vildagliptin+metformin      | Tab         | 50+500         | 75                         | 150                        | 2          | 100                |

Tab- tablet, SR- sustained release

**DISCUSSION**

Diabetes is a complex, chronic illness requiring long duration and expensive treatment. This affects not only patient’s quality of life but also imposes huge economic burden to both the family and society. It was evident from literature that rise in burden of diabetes can be due to high price variation among different brands of same drug.10-12

The compliance of patient also is significantly dependent on the cost of the prescribed medicines and higher cost means the compliance will be less.13 Selection of cost-effective brand will improve the compliance and the consequence of the treatment. The National pharmaceutical pricing authority (NPPA), of Government of India controls drug prices in Indian market. It fixes the ceiling price of a drug based on essentiality of a drug and the pharmaceutical companies fix the price for their products equal to or below the ceiling price for that formulation; however, they cannot sell any medicine given in the drugs prices control order (DPCO) list at a cost higher than that fixed under this order.14

Physicians should thus prescribe the low-cost drugs and should not be influenced by pharmaceutical industries. Even though government of India has insisted on prescribing drugs by their generic name there has been indifference among prescribing physicians towards the same.

There is a general belief among the common people including a fraction of prescribing physicians that costlier branded drugs are superior then their generic equivalents. Provision of readily available drug manual with comparative drug prices can ensure the doctor’s awareness about the cost variations among same generic medications. This can play an important role in decreasing patient’s drug expense. Decreased drug cost is an important factor for improved adherence to the medication regimen.

**CONCLUSION**

The study highlights that there is wide price variation of different brands of the same generic anti-diabetic drug in Indian market. To decrease the wide cost variation among different brands of anti-diabetic drugs; it is high time to generate physician awareness about impact of cost effectiveness of drug regimen and for regulation of drug prices by the concerned agencies.

Government should make a policy whereby the prices of branded-generic drugs can be made realistic and affordable to common person.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** The study was approved by the Institutional Ethics Committee
REFERENCES

1. Mayor S. Diabetes affecting nearly 250 million adults in the world. Br Med J. 2006;333:1191.
2. Kaveeswar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7(1):45-8.
3. International Diabetes federation. Diabetes atlas. 6th ed. IDF; 2003.
4. Kyle JS. A general overview of oral hypoglycemics for type 2 diabetes. Wyoming drug utilization review. 2008.
5. Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathological approach. 6th ed. New York, NY: McGraw-Hill; 2005: 1333.
6. Powers AC. Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, Mauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicines. 15th ed. New York, NY: McGraw-Hill; 2001: 2109-37.
7. Sakhivel S. Access to essential drugs and medicines. In: Commission on Macroeconomics and Health, Financing and delivery of health care services in India. New Delhi: Ministry of Health & Family Welfare, Government of India; 2005: 185-210.
8. Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol 2016;5:1636-40.
9. Shukla AK, Sharma P. Cost variation study of antidepressant drugs. Int J Basic Clin Pharmacol. 2016;5:1816-21.
10. Standards of Medical Care in Diabetes. American Diabetes Association Diabetes Care. 2014;37(1):14-80.
11. Lalan HN, Borde MK, Ray IM, Deshmukh YA. Cost Variation Study of Antidiabetics: Indian Scenario. Indian J Appl Res. 2014;4(5):420-1.
12. Rao KS, Nundy M, Dua AS, National commission on macroeconomics and health, financing and delivery of health care services in India. Government of India: Delivery of Health Services in the Private Sector. New Delhi: Ministry of Health and Family Welfare. 2005: 89-104.
13. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries BMJ Open. 2017;7:14287.
14. Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160:3.

Cite this article as: Gedam S, Barmaiya N. Cost variation analysis of oral anti-diabetic agents available in Indian market. Int J Basic Clin Pharmacol 2021;10:694-8.